Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT07217717

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

Led by SOFIE · Updated on 2026-04-20

200

Participants Needed

10

Research Sites

107 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed pancreatic ductal adenocarcinoma. Following screening, using a standardized administration protocol and dose, participants will undergo \[¹⁸F\]FAPI-74 PET/CT screening. SOC procedures and interventions will be captured during 3 months +/-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \[¹⁸F\]FAPI-74 PET/CT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow up. The participants will be followed-up for safety for 24 to 72 hours after the dose of \[¹⁸F\]FAPI-74 PET/CT.

CONDITIONS

Official Title

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female adults 18 years or older
  • Confirmed pancreatic ductal adenocarcinoma undergoing staging for treatment planning
  • Eastern Cooperative Oncology Group (ECOG) performance status 2 or less
  • Signed informed consent before any study procedures
  • Required to have a contrast-enhanced CT scan of chest, abdomen, and pelvis within 21 days before or planned within 21 days of [18F]FAPI-74 administration
  • Women who are not postmenopausal or surgically sterile must agree to use effective contraception during the trial
Not Eligible

You will not qualify if you...

  • Clear evidence of metastases that rules out surgery at enrollment
  • Known allergy to [18F]FAPI-74
  • Received another investigational product within 30 days before [18F]FAPI-74 administration
  • Received a radiopharmaceutical within 10 half-lives before [18F]FAPI-74 administration
  • Previous cancer diagnosis except basal cell skin cancer or in situ cervical/uterine carcinoma unless disease-free for over 5 years
  • Liver function with total bilirubin over 1.5 times upper limit or alkaline phosphatase, ALT, or AST over 5 times upper limit
  • Kidney function with GFR less than 30 mL/min
  • Pregnant or breastfeeding women (negative pregnancy test required for women of childbearing potential)
  • Unable to undergo PET/CT scan
  • Having inflammatory bowel disease like Crohn's disease or ulcerative colitis
  • Having sarcoidosis
  • Receiving treatment such as chemotherapy, radiation, or surgery for curative intent of PDAC

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Helios CR Inc./RadNet

Cerritos, California, United States, 90703

Actively Recruiting

2

Hoag Memorial Hospital

Irvine, California, United States, 92618

Actively Recruiting

3

UCLA

Los Angeles, California, United States, 90095

Actively Recruiting

4

Moffit Cancer Center

Tampa, Florida, United States, 33612

Actively Recruiting

5

Indiana University Health University Hospital

Indianapolis, Indiana, United States, 46202

Actively Recruiting

6

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

7

UMass/Shields

Worcester, Massachusetts, United States, 01655

Actively Recruiting

8

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Actively Recruiting

9

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Actively Recruiting

10

Kettering

Kettering, Ohio, United States, 45429

Actively Recruiting

Loading map...

Research Team

A

Alex Osipova

CONTACT

B

Bridget Adams

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here